Susetiati Devi Artami, Pudjiati Satiti Retno, Wirohadidjojo Yohanes Widodo, Chandra Lukman Ade
Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Indonesia.
Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Indonesia.
J Int Med Res. 2025 Aug;53(8):3000605251363006. doi: 10.1177/03000605251363006. Epub 2025 Aug 5.
ObjectiveThis study evaluated the therapeutic efficacy of in women with cervical human papillomavirus infection. Specifically, it aimed to assess the impact of therapy on human papillomavirus clearance and cervical lesion resolution in clinical settings.MethodsA literature search was conducted in October 2024 using PubMed, EBSCO, Google Scholar, and ScienceDirect. Eligible studies included randomized controlled trials and quasi-randomized controlled trials investigating therapy for human papillomavirus infection. This review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Risk of bias was assessed using the risk of bias 2.0 and ROBINS-I (Risk Of Bias In Non-randomized Studies - of Interventions) tools. Data were analyzed using a random-effects model with 95% confidence intervals, and heterogeneity was evaluated using the statistic. A subgroup analysis was performed based on the method of administration (oral vs. vaginal).ResultsFive studies were included in the meta-analysis. Among 326 participants assessed for lesion resolution, therapy showed a statistically significant improvement (relative risk = 1.93, 95% confidence interval: 1.47-2.53, p < 0.00001; = 0%). Similarly, among the 262 participants assessed for viral clearance, the treatment showed a statistically significant effect (relative risk = 1.39, 95% confidence interval: 1.00-1.94, p = 0.05; = 33%).ConclusionIn patients with low-grade squamous intraepithelial lesions/atypical squamous cells of undetermined significance cervical lesions, therapy administered over a minimum duration of 6 months may serve as an adjuvant treatment for human papillomavirus infection.
目的
本研究评估了[具体治疗方法未给出]对宫颈人乳头瘤病毒感染女性的治疗效果。具体而言，其旨在评估在临床环境中[具体治疗方法未给出]疗法对人乳头瘤病毒清除和宫颈病变消退的影响。
方法
2024年10月使用PubMed、EBSCO、谷歌学术和科学Direct进行文献检索。符合条件的研究包括调查[具体治疗方法未给出]疗法治疗人乳头瘤病毒感染的随机对照试验和半随机对照试验。本综述遵循系统评价和荟萃分析的首选报告项目指南。使用偏倚风险2.0和ROBINS - I（非随机干预研究中的偏倚风险）工具评估偏倚风险。数据使用具有95%置信区间的随机效应模型进行分析，异质性使用Q统计量进行评估。基于给药方法（口服与阴道给药）进行亚组分析。
结果
五项研究纳入荟萃分析。在评估病变消退的326名参与者中，[具体治疗方法未给出]疗法显示出统计学上的显著改善（相对风险 = 1.93，95%置信区间：1.47 - 2.53，p < 0.00001；I² = 0%）。同样，在评估病毒清除的262名参与者中，该治疗显示出统计学上的显著效果（相对风险 = 1.39，95%置信区间：1.00 - 1.94，p = 0.05；I² = 33%）。
结论
在低度鳞状上皮内病变/意义不明确的非典型鳞状细胞宫颈病变患者中，至少持续6个月给予[具体治疗方法未给出]疗法可作为人乳头瘤病毒感染的辅助治疗。
